Full Prescribing Information

Full Prescribing Information

Important Safety Information

Healthcare Professionals Site

ADDING STRONTIUM89

Works well with other treatments

If your or your loved one’s current pain treatment plan isn’t providing adequate bone pain control, talk to your cancer care team. When added to many commonly used cancer treatments or to pain therapies, Strontium89 can effectively provide relief for painful bone mets.

  • Strontium89 + external beam radiation therapy (EBRT)
  • Strontium89 + chemotherapy (including cisplatin)
  • Strontium89 + zoledronic acid
  • Strontium89 + androgen deprivation therapy (ADT)/androgen suppression therapy (AST)

Strontium89 was well-tolerated and effective when used with other common cancer treatments

In a study with chemotherapy, cisplatin*

  • 91% of participants receiving Strontium89 plus cisplatin found overall pain relief compared with 63% of participants treated with Strontium89 alone
  • Relief lasted for a median of 120 days in the Strontium89 plus cisplatin group compared with 60 days in the group treated with Strontium89 alone

In a study with the bone strengthening drug, zoledronic acid†

  • 94% of participants responded to combination treatment, showing a reduction of pain
  • Participants experienced significant relief of bone pain across multiple types of primary cancer, including prostate, breast, and lung
*In a randomized phase III trial (n=70) comparing equal groups of participants receiving either Strontium89 plus cisplatin (arm A) with Strontium89 plus placebo (arm B).
†In a study of participants with various types of cancer and painful bone metastases (n=51), found that pain due to bone metastases was significantly improved (P<0.001) across multiple types of primary cancer, including prostate, breast, and lung, with no grade significant bone marrow suppression.
Icon/Talk to Doctor

SUPPORT AND RESOURCES

We’re here to support you with resources and tips for talking to your doctor about painful bone mets and Strontium89.

VIEW

Indication and important safety information

INDICATION

Strontium89 (Strontium Chloride Sr-89 Injection, USP) is used for the relief of bone pain in patients with bone metastases. You should only use Strontium89 if you have been diagnosed with metastatic bone cancer.

IMPORTANT SAFETY INFORMATION

  • Strontium89 may affect bone marrow and may cause white blood cell and platelet counts to be lower than normal. To monitor these effects, your doctor will perform regular blood tests before and after your injection, usually at least every other week until your levels have recovered. This may take up to 6 months. Your doctor will decide if it is safe for you to get a repeat injection, 90 days later, if needed. If you already have seriously decreased bone marrow function, your doctor may decide that you should not receive Strontium89.
  • Tell your doctor if you are pregnant or planning to become pregnant. Strontium89 may cause harm to your unborn baby and should not be used if you are pregnant or planning to become pregnant. You should not nurse your baby while using Strontium89.
  • You should not use Strontium89 if you do not have cancer in your bone.
  • You should not use Strontium89 if you are younger than 18 years old.
  • You may feel flushed (your skin may get red and warm) right after your injection.
  • Side effects in clinical studies:
    • One patient died from a blood infection caused by a severely low white blood cell count.
    • A small number of patients reported a mild and brief increase in bone pain within 36 to 72 hours after injection that was controlled with oral pain medication.
    • One patient had chills and fever 12 hours after injection but recovered.
These are not all of the side effects of Strontium89. If you have any questions or concerns about side effects, you should contact your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.FDA.gov/medwatch or call (800) FDA-1088.

Please see full Prescribing Information

TOP

Contact Us

If you have questions about Strontium89 or would like to report an adverse event,

©2021 Q BioMed Inc. All rights reserved. US-SR89WEB_0010 MAR2021

The information contained in this section is intended for US healthcare professionals only.

Proceed
Cancel